23 January 2020 - - US-based synthetic biology company Twist Bioscience Corp. (NASDAQ: TWST) has forged a collaboration with Schrödinger, Inc., a company focused on transforming the way therapeutics are discovered with a physics-based computational platform, to bring the two companies' technology platforms together to discover new antibody therapeutics against G-protein coupled receptor targets, the company said.

Under the terms of the agreement, each company will contribute their individual expertise in a highly collaborative manner to discover novel antibody therapeutics.

Specifically, Schrödinger will use its proprietary physics-based computational platform to model functional antibody segments that bind to a particular GPCR receptor.

Twist Biopharma, a division of Twist Bioscience, will then use its silicon-based DNA synthesis platform to generate a large number of precisely defined antibody sequences that can then be taken into proof-of-concept and preclinical development.

The companies will collaborate on any commercial opportunities generated by the work together.

Twist Bioscience is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.

The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip.

Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing preparation, and antibody libraries for drug discovery and development.

Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.